Pasar al contenido principal

DESCIFRANDO LAS BASES MOLECULARES DE ENFERMEDADES RENALES MEDIADAS POR EL COMPLEMENTO

RTI2018-095955-B-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD COMPLUTENSE DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Longitudinal change in proteinuria and kidney outcomes in C3 glomerulopathy

  • Caravaca-Fontán, Fernando
  • Díaz-Encarnación, Montserrat M.
  • Cabello, Virginia
  • Ariceta, Gema
  • Quintana, Luis F.
  • Marco, Helena
  • Barros, Xoana
  • Ramos, Natalia
  • Rodríguez-Mendiola, Nuria
  • Cruz, Sonia
  • Fernández-Juárez, Gema
  • Rodríguez, Adela
  • Pérez de José, Ana
  • Rabasco, Cristina
  • Rodado, Raquel
  • Fernández, Loreto
  • Pérez Gómez, Vanessa
  • Ávila, Ana
  • Bravo, Luis
  • Espinosa, Natalia
  • Allende, Natalia
  • Sánchez de la Nieta, María Dolores
  • Rodríguez, Eva
  • Olea, Teresa
  • Melgosa, Marta
  • Huerta, Ana
  • Miquel, Rosa
  • Mon, Carmen
  • Fraga, Gloria
  • de Lorenzo, Alberto
  • Draibe, Juliana
  • Cano-Megías, Marta
  • González, Fayna
  • Shabaka, Amir
  • López-Rubio, María Esperanza
  • Fenollosa, María Ángeles
  • Martín-Penagos, L.
  • Da Silva, Iara
  • Alonso Titos, Juana
  • Rodríguez de Córdoba, Santiago
  • Goicoechea de Jorge, Elena
  • Praga, Manuel
  • Spanish Group for the Study of Glomerular Diseases (GLOSEN)
11 p.-4 fig.-4 tab., Introduction: The association between a change in proteinuria over time and its impact in kidney prognosis has not been analyzed in C3 glomerulopathy. This study aims to investigate the association between the longitudinal change in proteinuria and the risk of kidney failure., Methods: Retrospective, multicenter observational cohort study in 35 nephrology departments belonging to the Spanish Group for the Study of Glomerular Diseases (GLOSEN). Patients diagnosed with C3 glomerulopathy between 1995 and 2020 were enrolled. A joint modeling of linear mixed-effects models was applied to assess the underlying trajectory of a repeatedly measured proteinuria, and a Cox model to evaluate the association of this trajectory with the risk of kidney failure., Results: The study group consisted of 85 patients, 70 C3 glomerulonephritis and 15 dense deposit disease, with a median age of 26 years (range 13-41). During a median follow-up of 42 months, 25 patients reached kidney failure. The longitudinal change in proteinuria showed a strong association with the risk of this outcome, with a doubling of proteinuria levels resulting in a 2.5-fold increase of the risk. A second model showed that a ≥ 50% proteinuria reduction over time was significantly associated with a lower risk of kidney failure (HR: 0.79; 95% CI : 0.56-0.97; p < 0.001). This association was also found when the ≥50% proteinuria reduction was observed within the first 6 and 12 months of follow-up., Conclusion: The longitudinal change in proteinuria is strongly associated with the risk of kidney failure. The change in proteinuria over time can provide clinicians a dynamic prediction of kidney outcomes., This study was supported by the Instituto de Salud Carlos III/Fondo Europeo de Desarrollo Regional (ISCIII/FEDER) grant PI16/01685 and PI19/1624, and Red de Investigación Renal (RedInRen) (RD12/0021/0029) (to M.P.), the Autonomous Region of Madrid (S2017/BMD-3673) (to M.P.); E.G.d.J. was supported by the Spanish ‘Ministerio de Ciencia, Innovación y Universidades’ (RYC-2013-13395 and RTI2018-095955-B-100); S.R.d.C. was supported by Ministerio de Economía y Competitividad/FEDER grant SAF2015-66287R and Autonomous Region of Madrid grant S2017/BMD3673., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Factor H-related protein 1 drives disease susceptibility and prognosis in C3 glomerulopathy

  • Márquez-Tirado, Bárbara
  • Gutiérrez-Tenorio, Josué
  • Tortajada, Agustín
  • Lucientes, Laura
  • Caravaca-Fontán, Fernando
  • Malik, T. H.
  • Roldán Montero, Raquel
  • Elías, Sandra
  • Saiz Gonzalez, Ana
  • Fernández-Juárez, Gema
  • Sánchez-Corral, Pilar
  • Pickering, Matthew C.
  • Praga, Manuel
  • Rodríguez de Córdoba, Santiago
  • Goicoechea de Jorge, Elena
17 p.-8 fig., Background: C3 glomerulopathy (C3G) is a heterogeneous group of chronic renal diseases characterized predominantly by glomerular C3 deposition and complement dysregulation. Mutations in factor H-related (FHR) proteins resulting in duplicated dimerization domains are prototypical of C3G, although the underlying pathogenic mechanism is unclear., Methods: Using in vitro and in vivo assays, we performed extensive characterization of an FHR-1 mutant with a duplicated dimerization domain. To assess the FHR-1 mutant's association with disease susceptibility and renal prognosis, we also analyzed CFHR1 copy number variations and FHR-1 plasma levels in two Spanish C3G cohorts and in a control population., Results: Duplication of the dimerization domain conferred FHR-1 with an increased capacity to interact with C3-opsonized surfaces, which resulted in an excessive activation of the alternative pathway. This activation does not involve C3b binding competition with factor H. These findings support a scenario in which mutant FHR-1 binds to C3-activated fragments and recruits native C3 and C3b; this leads to formation of alternative pathway C3 convertases, which increases deposition of C3b molecules, overcoming FH regulation. This suggests that a balanced FHR-1/FH ratio is crucial to control complement amplification on opsonized surfaces. Consistent with this conceptual framework, we show that the genetic deficiency of FHR-1 or decreased FHR-1 in plasma confers protection against developing C3G and associates with better renal outcome., Conclusions: Our findings explain how FHR-1 mutants with duplicated dimerization domains result in predisposition to C3G. They also provide a pathogenic mechanism that may be shared by other diseases, such as IgA nephropathy or age-related macular degeneration, and identify FHR-1 as a potential novel therapeutic target in C3G., E. Goicoechea de Jorge is supported by Ministerio de Ciencia e Innovación grant RTI2018-095955-B-100 and the European Union’s Horizon 2020 Framework Programme grant 899163. J. Gutiérrez-Tenorio is supported by Ministerio de Ciencia e Innovación grant BES-2015-073833. L. Lucientes Continente is supported by the Autonomous Region of Madrid grant S2017/BMD-3673. G. Fernández-Juarez, P. Sánchez-Corral, B. Márquez-Tirado, and M. Praga are supported by the Instituto de Salud Carlos III and the European Union’s European Regional Development Fund grants PI19/01695, PI19/00970, and PI19/01624, respectively. M.C. Pickering is a Wellcome Trust Senior Fellow in Clinical Science (212252/Z/18/Z). S. Rodríguez de Córdoba is supported by the Ministerio de Economía y Competitividad grant PID2019-104912RB-100 and Autonomous Region of Madrid grant S2017/BMD-3673., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Thrombotic microangiopathy in patients with malignant hypertension

  • Cavero, Teresa
  • Auñón, Pilar
  • Caravaca-Fontán, Fernando
  • Trujillo, Hernando
  • Arjona, Emilia
  • Morales, Enrique
  • Guillén, Elena
  • Blasco, Miquel
  • Rabasco, Cristina
  • Espinosa, Mario
  • Blanco, Marta
  • Rodríguez-Magariños, Catuxa
  • Cao, Mercedes
  • Ávila, Ana
  • Huerta, Ana
  • Rubio, Esther
  • Cabello-Chaves, Virginia
  • Barros, Xoana
  • Goicoechea de Jorge, Elena
  • Rodríguez de Córdoba, Santiago
  • Praga, Manuel
10 p.-4 fig.-4 tab., Background: Thrombotic microangiopathy (TMA) is a complication of malignant hypertension (mHTN) attributed to high blood pressure (BP). However, no studies have investigated in patients with mHTN of different aetiologies whether the presence of TMA is associated with specific causes of mHTN., Methods: We investigated the presence of TMA (microangiopathic haemolytic anaemia and thrombocytopenia) in a large and well-characterized cohort of 199 patients with mHTN of different aetiologies [primary HTN 44%, glomerular diseases 16.6%, primary atypical haemolytic uraemic syndrome (aHUS) 13.1%, renovascular HTN 9.5%, drug-related HTN 7%, systemic diseases 5.5%, endocrine diseases 4.5%]. Outcomes of the study were kidney recovery and kidney failure., Results: Patients with TMA [40 cases (20.1%)] were younger, were more likely female and had lower BP levels and worse kidney function at presentation. Their underlying diseases were primary aHUS (60%), drug-related mHTN (15%), glomerular diseases [all of them immunoglobulin A nephropathy (IgAN); 10%], systemic diseases (10%) and primary HTN (5%). The presence of TMA was 92.3% in primary aHUS, 42.9% in drug-related HTN, 36.4% in systemic diseases, 12.1% in glomerular diseases and 2.3% in primary HTN. No patient with renovascular HTN or mHTN caused by endocrine diseases developed TMA, despite BP levels as high as patients with TMA. A higher proportion of TMA patients developed kidney failure as compared with patients without TMA (56.4% versus 38.9%, respectively)., Conclusions: The presence of TMA in patients with mHTN should guide the diagnosis towards primary aHUS, drug-related mHTN, some systemic diseases and IgAN, while it is exceptional in other causes of mHTN., Work in this study was supported by the Instituto de Salud Carlos III/Fondo Europeo de Desarrollo Regional [ISCIII/FEDER;grants PI13/02502 and PICI14/00350 (to M.P.) and PI16/01685 and PI19/01624 (to M.P. and T.C.)]; the Spanish Ministerio de Economía y Competitividad/FEDER [SAF2015-66287-R and PID2019-104912RB-I00 (to S.R.d.C.)]; the Spanish ‘Ministerio de Ciencia Innovación y Universidades’ [RTI2018-095955-B-100 (to E.G.J.)]; the Autonomous Region of Madrid [S2017/BMD-3673 (to E.G.J., S.R.d.C. and M.P.)] and Red de Investigación Renal [RD12/0021/0029 (to M.P.)]., Peer reviewed
Docta Complutense
Publicación Artículo científico (JournalArticle)

The Factor H protein family: The switchers of the complement alternative pathway

  • Lucientes Continente, Laura
  • Márquez Tirado, Bárbara
  • Goicoechea de Jorge, Elena
The factor H (FH) protein family is emerging as a complex network of proteins controlling the fate of the complement alternative pathway (AP) and dictating susceptibility to a wide range of diseases including infectious, inflammatory, autoimmune, and degenerative diseases and cancer. Composed, in man, of seven highly related proteins, FH, factor H-like 1, and 5 factor H-related proteins, some of the FH family proteins are devoted to down-regulating the AP, while others exert an opposite function by promoting AP activation. Recent findings have provided insights into the molecular mechanisms defining their biological roles and their pathogenicity, illustrating the relevance that the balance between the regulators and the activators within this protein family has in defining the outcome of complement activation on cell surfaces. In this review we will discuss the emerging roles of the factor H protein family, their impact in the complement cascade, and their involvement in the pathogenesis of complementmediated diseases associated with the AP dysregulation.